Interim Report - January-June 2024

STOCKHOLM – 30 August 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report - January-June 2024. The full report is available on the Company's website.“The successes that we have summarized from the quarter give a good picture of the important activities taking place within the portfolio, and we look forward to an equally intense autumn. Our most recent addition to the portfolio, BOOST Pharma, is, for example, expected to present the final results of...

Solna, 30/08/2024 (informazione.it - comunicati stampa - servizi)

STOCKHOLM – 30 August 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report - January-June 2024. The full report is available on the Company's website.

“The successes that we have summarized from the quarter give a good picture of the important activities taking place within the portfolio, and we look forward to an equally intense autumn. Our most recent addition to the portfolio, BOOST Pharma, is, for example, expected to present the final results of its clinical phase 1/2 study before the end of the year”, says Viktor Drvota, CEO, Karolinska Development.

Significant events during the second quarter

Significant post-period events

Financial update

The Interim Report for Karolinska Development AB for the period January-June 2024 is available as a PDF at www.karolinskadevelopment.com .

For further information, please contact:

Viktor Drvota, CEO, Karolinska Development AB
Phone: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.com

Hans Christopher “HC” Toll, CFO, Karolinska Development AB        
Phone: +46 70 717 00 41, e-mail: hc.toll@karolinskadevelopment.com

TO THE EDITORS

About Karolinska Development AB

Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients' lives while providing an attractive return on investment to shareholders.

Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.

Karolinska Development has established a portfolio of twelve companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.

The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.

For more information, please visit www.karolinskadevelopment.com

Attachments